Comparison of the efficacy and safety of statin and statin/ezetimibe therapy after coronary stent implantation in patients with stable angina

Journal of Cardiology

Volumn 60, Issue 2, 2012, Pages 111-118

  Arimura, Tadaaki ^a   Miura, Shin Ichiro ^a   Ike, Amane ^a   Sugihara, Makoto ^a   Iwata, Atsushi ^a   Nishikawa, Hiroaki ^a   Kawamura, Akira ^a   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Ezetimibe; Lipid; Restenosis; Statin

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; C REACTIVE PROTEIN; CLOPIDOGREL; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TICLOPIDINE;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIAC PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY STENT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; IMPLANTATION; IN-STENT RESTENOSIS; MALE; OUTCOME ASSESSMENT; STABLE ANGINA PECTORIS;

AGED; ANGINA, STABLE; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; CORONARY ANGIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; STENTS; TREATMENT OUTCOME;

EID: 84865351117     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2012.03.002     Document Type: Article

References (31)

1. Serruys P.W., de Feyter P., Macaya C., Kokott N., Puel J., Vrolix M., Branzi A., Bertolami M.C., Jackson G., Strauss B., Meier B. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002, 287:3215-3222. Lescol Intervention Prevention Study (LIPS) Investigators.
2. Tsunoda R., Sakamoto T., Kojima S., Ogata Y., Kitagawa A., Ogawa H. Recurrence of angina pectoris after percutaneous coronary intervention is reduced by statins in Japanese patients. J Cardiol 2011, 58:208-215.
3. Nakamura M., Yamashita T., Yajima J., Oikawa Y., Ogasawara K., Sagara K., Koike A., Kirigaya H., Nagashima K., Otsuka T., Uejima T., Funada R., Matsuno S., Suzuki S., Sawada H., et al. Impact of early statin initiation on secondary prevention in Japanese patients with coronary artery disease. J Cardiol 2011, 57:172-180.
4. Zhang Z.J. Mortality benefit and reduced need for repeat revascularization with statin therapy among patients undergoing percutaneous coronary intervention. J Cardiol 2011, 57:360-361.
5. Teramoto T., Sasaki J., Ueshima H., Egusa G., Kinoshita M., Shimamoto K., Daida H., Biro S., Hirobe K., Funahashi T., Yokote K., Yokode M. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 2007, 14:45-50.
6. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., Gotto A.M., Greten H., Kastelein J.J., Shepherd J., Wenger N.K. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1435. Treating to New Targets (TNT) Investigators.
7. Iwata A., Mira S., Shirai K., Kawamura A., Tomita S., Matsuo Y., Zhang B., Nishikawa H., Kumagai K., Matsuo K., Saku K. Lower level of low-density lipoprotein cholesterol by statin prevents progression of coronary restenosis after successful stenting in acute myocardial infarction. Intern Med 2006, 45:885-890.
8. Takamiya Y., Miura S., Kawamura A., Tanigawa H., Zhang B., Iwata A., Nishikawa H., Matsuo K., Shirai K., Saku K. Intensive lowering of blood pressure and low-density lipoprotein cholesterol with statin therapy may improve neointimal formation after coronary stenting in patients with coronary artery disease (LOBOCOP). Coron Artery Dis 2009, 20:288-294.
9. Clader J.W. The discovery of ezetimibe: a view from outside the receptor. J Med Chem 2004, 47:1-9.
10. Strandberg T.E., Tilvis R.S., Pitkala K.H., Miettinen T.A. Cholesterol and glucose metabolism and recurrent cardiovascular events among the elderly: a prospective study. J Am Coll Cardiol 2006, 48:708-714.
11. Matthan N.R., Pencina M., LaRocque J.M., Jacques P.F., D'Agostino R.B., Schaefer E.J., Lichtenstein A.H. Alterations in cholesterol absorption/synthesis markers characterize Framingham offspring study participants with CHD. J Lipid Res 2009, 50:1927-1935.
12. Miettinen T.A., Gylling H., Lindbohm N., Miettinen T.E., Rajaratnam R.A., Relas H. Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins. J Lab Clin Med 2003, 141:131-137. Finnish Treat-to-Target Study Investigators.
13. Davidson M.H., McGarry T., Bettis R., Melani L., Lipka L.J., LeBeaut A.P., Suresh R., Sun S., Veltri E.P. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002, 40:2125-2134.
14. Bulut D., Hanefeld C., Bulut-Streich N., Graf C., Mügge A., Spiecker M. Endothelial function in the forearm circulation of patients with the metabolic syndrome--effect of different lipid-lowering regimens. Cardiology 2005, 104:176-180.
15. Kastelein J.J., Akdim F., Stroes E.S., Zwinderman A.H., Bots M.L., Stalenhoef A.F., Visseren F.L., Sijbrands E.J., Trip M.D., Stein E.A., Gaudet D., Duivenvoorden R., Veltri E.P., Marais A.D., de Groot E., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008, 358:1431-1443.
16. Okada K., Kimura K., Iwahashi N., Endo T., Himeno H., Fukui K., Kobayashi S., Shimizu M., Iwasawa Y., Morita Y., Wada A., Shigemasa T., Mochida Y., Shimizu T., Sawada R., et al. Clinical usefulness of additional treatment with ezetimibe in patients with coronary artery disease on statin therapy. Circ J 2011, 75:2496-2504.
17. Nissen S.E., Tuzcu E.M., Schoenhagen P., Crowe T., Sasiela W.J., Tsai J., Orazem J., Magorien R.D., O'Shaughnessy C., Ganz P. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005, 352:29-38. Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators.
18. Herrmann J., Lerman A., Baumgart D., Volbracht L., Schulz R., von Birgelen C., Haude M., Heusch G., Erbel R. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation 2002, 106:2180-2183.
19. Chan A.W., Bhatt D.L., Chew D.P., Quinn M.J., Moliterno D.J., Topol E.J., Ellis S.G. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002, 105:691-696.
20. Pasceri V., Patti G., Nusca A., Pristipino C., Richichi G., Di Sciascio G. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004, 110:674-678. ARMYDA Investigators.
21. Nicholls S.J., Tuzcu E.M., Sipahi I., Grasso A.W., Schoenhagen P., Hu T., Wolski K., Crowe T., Desai M.Y., Hazen S.L., Kapadia S.R., Nissen S.E. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007, 297:499-508.
22. von Birgelen C., Hartmann M., Mintz G.S., van Houwelingen K.G., Deppermann N., Schmermund A., Böse D., Eggebrecht H., Neumann T., Gössl M., Wieneke H., Erbel R. Relationship between cardiovascular risk as predicted by established risk scores versus plaque progression as measured by serial intravascular ultrasound in left main coronary arteries. Circulation 2004, 110:1579-1585.
23. Savchenko A., Imamura M., Ohashi R., Jiang S., Kawasaki T., Hasegawa G., Emura I., Iwanari H., Sagara M., Tanaka T., Hamakubo T., Kodama T., Naito M. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol 2008, 215:48-55.
24. Prasado K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 2006, 24:33-50.
25. Sugihara M., Miura S., Takamiya Y., Kiya Y., Arimura T., Iwata A., Kawamura A., Nishikawa H., Uehara Y., Saku K. Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation. Hypertens Res 2009, 32:625-630.
26. Davidson M.H., Ballantyne C.M., Kerzner B., Melani L., Sager P.T., Lipka L., Strony J., Suresh R., Veltri E. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract 2004, 58:746-755. Ezetimibe Study Group.
27. Goldberg A.C., Sapre A., Liu J., Capece R., Mitchel Y.B. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004, 79:620-629. Ezetimibe Study Group.
28. Lipka L., Sager P., Strony J., Yang B., Suresh R., Veltri E. Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia. Drugs Aging 2004, 21:1025-1032. Ezetimibe Study Group.
29. Nakata M., Nagasaka S., Kusaka I., Matsuoka H., Ishibashi S., Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): Implications in glycaemic control. Diabetologia 2006, 49:1881-1892.
30. Yamakawa T., Takano T., Tanaka S., Kadonosono K., Terauchi Y. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2008, 15:269-275.
31. Petronio A.S., Amoroso G., Limbruno U., Papini B., De Carlo M., Micheli A., Ciabatti N., Mariani M. Simvastatin does not inhibit intimal hyperplasia and restenosis but promotes plaque regression in normocholesterolemic patients undergoing coronary stenting: a randomized study with intravascular ultrasound. Am Heart J 2005, 149:520-526.